



Date: 29<sup>th</sup> November, 2025

To,  
BSE Limited  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal street- Fort  
Mumbai-40001.

Scrip Code: 539730

**Subject: Corrigendum through General Announcement regarding disclosure of Ultimate Beneficial Owners (UBOs), Pre-Preferential Shareholding of Proposed Allottees and bifurcation and brief description of the object in connection with the Extra-Ordinary General Meeting (EGM) held on October 22, 2025.**

Dear Sir/ Madam,

With reference to the Notice of the Extra-Ordinary General Meeting ("EGM") of Fredun Pharmaceuticals Limited ("the Company") dated September 30, 2025, the Corrigendum to the EGM Notice dated October 17, 2025 and the resolutions passed at the EGM held on October 22, 2025 relating to the preferential issue of Equity Shares and Warrants, the Company hereby issues this general announcement to ensure full transparency and compliance.

The Company is providing a consolidated and updated statement of:

- (i) Ultimate Beneficial Owners (UBOs) of the proposed allottees, wherever applicable and required,
- (ii) Pre-preferential shareholding of all proposed allottees and
- (iii) Bifurcation and Brief description of the object of the issue - attached as "Annexure A"





i) The revised consolidated lists of the proposed allottees along with their respective UBOs details are as follows:

Sr. No.	Name of the proposed allottees	Name of the UBOs	PAN of the UBOs
1	Alchemy Capital Management Pvt Ltd	Mr. Lashit Lallubhai Sanghvi	AAHPS6774J
		Mr. Ashwin Kedia	ACGPK7677P
		Mrs. Rekha Jhunjhunwala, Principal executor on behalf of "Estate of Late Shri. Rakesh Jhunjhunwala")	AAEPJ2191B
2	R R Family Trust	Mr. Ramesh Thakurdas Jaisinghani	AACPJ2100L
		Ms. Reina Ramesh Jaisinghani	ADUPJ4939L
3	Priyabhakta Commotrade Private Limited	Mr. Akhilesh Saraogi	AMAPS1312B
		Ms. Shruti Saraogi	ATYPS2728Q
4	Somani Stock Broking Pvt Ltd	Mr. Rajesh Kumar Somani	AJMPS2279N
		Mr. Rakesh Somani	AJMPS2281G
		Ms. Sushila Somani	AJPS2451D
5	Aryavrat Financial Services Private Limited	Mr. Raj Kumar Agarwal	ACKPA0021B
6	Sona Vets Private Limited	Mr. Sameer Agarwal	ACQPA9823M
7	NAV Capital VCC-NAV Capital Emerging Star Fund	Mr. Veerendra Kedarnath Chandalada	ADCPC4142Q
8	Nav Bharat Investment Trust- Nav Bharat Investment Opportunities Fund	Mr. Ravindra Dutt Tyagi	ABXPT5951F
		Mr. Anita Tyagi	ACZPT0074E
		Mr. Vineet Arora	ACJPA6994L
		Mr. Jatin Agarwal	BWBPA9131Q
9	H&A Ventures (On behalf of Shipra Bhutra)	Ms. Priyanka Himanshu Jain	BFYPM1771E
		Ms. Shipra Abhishek Bhutra	BJPPB6877F
10	Capri Global Holdings Private Limited	Mr. Rajesh Sharma	AMBPS1495A
11	Dhananjay Advisors (On behalf of Ritu Rani)	Ms. Ritu Rani	AJFPR6068P
12	Instanow Info Systems Private Limited	Mr. Pramod Agarwal	AGMPA0693H
		Mr. Mahesh Kumar	ATGPK1597F
		Mr. Mohit	AZIPM3804D
		Mr. Deepak Kumar	BTAPD2948E
		Mr. Aryan Tyagi	BINPT0384A



# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*

CIN No : L24239MH1987PLC043662



13	Rajesh Suryakant Gandhi (HUF)	Mr. Rajesh Suryakant Gandhi	ADZPG2163J
14	Czar Capital Private Limited	Mrs. Sonal Kothari	BOOPK2624B
15	Hiten B Shah HUF	Ms. Sejal Jhaveri	AHZPJ9699N
16	Ceramet Consultants Private Limited	Mr. Hiten B Shah	AADPS7814B
17	Shagun Capital Venture (On behalf of Shankesh Vijaykumar and Manav Vijaykumar)	Mr. Aniket Gore	ADHPG1568M
18	Gunchandra C. Mehta HUF	Mr. Shankesh Vijaykumar	LKNPS0492N
		Mr. Manav Vijaykumar	CEEPV1801C
		Mr. Amit Mehta	AAFPM4855J

## ii) Details of pre-preferential shareholding of the allottees:

Name of the Allottee	Pre-preferential shareholding (No. of shares)	Whether pre-preferential shareholding in physical/demat	Lock in Details		Pledge Details	
			Date From	Date To	No of shares	Name of institution
Fredun Nariman Medhora	1,79,672	Demat	01-10-2025	31-05-2026	NA	
Daulat Nariman Medhora	14,10,898	Demat	01-10-2025	31-05-2026	NA	
Nikhil Ramesh Jaisinghani	11	Demat	02-10-2025	31-05-2026	NA	
Prithvirama chandra Vashist	880	Demat	01-10-2025	31-05-2026	NA	

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No: L24239MH1987PLC043662					
Rajesh Suryakant Gandhi (HUF)	30	Demat	01-10-2025	31-05-2026	NA
Tanvi Achariya	6,608	Demat	02-10-2025	31-05-2026	NA
M/s. Gunchandra C Mehta HUF	10	Demat	17-10-2025	31-05-2026	NA
TOTAL	15,98,109				

The above details supersede any disclosures regarding UBOs in the earlier communications (Notice of EGM and Corrigendum dated October 17, 2025) and shall be read in conjunction with the original terms and conditions set out in the Notice of the EGM.

We confirm that this clarification does not change the nature, terms, or conditions of the proposed allotment, the resolutions passed, or the rights/obligations of any stakeholder.

Kindly take the above on record.

Thanking You,  
Yours faithfully,

**FOR FREDUN PHARMACEUTICALS LIMITED**

**FREDUN MEDHORA  
MANAGING DIRECTOR  
DIN: 01745348**

**PLACE: MUMBAI**

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: [business@fredungroup.com](mailto:business@fredungroup.com) Web: [www.fredungroup.com](http://www.fredungroup.com)



## **ANNEXURE A**

### **Utilisation of Funds**

<b>Sr.No</b>	<b>Particulars</b>	<b>Total estimated amount to be utilised for each of the Objects (` in Crores)</b>	<b>Tentative Timeline for Utilization of Issue Proceeds from the date of receipt of funds</b>	<b>Reason for providing broad range for estimated amount to be utilised</b>
1	Brand Marketing & Distribution	49-53	<b>12 to 24 months</b>	The estimated expenditure may vary based on market conditions, campaign scale, media mix, and distribution expansion requirements across regions.
2	CAPEX	6-7	<b>9 to 12 months</b>	The variation arises due to potential changes in vendor quotations, equipment specifications, installation costs, and project execution timelines.
3	Formulation Development & R&D	7-8	<b>12 to 18 months</b>	The R&D-related costs may fluctuate depending on trial outcomes, raw material pricing, regulatory requirements, and the need for additional testing or modifications.

4	Strategic & Statutory Reserves	22-25	<b>18 to 24 months</b>	A broad range is provided considering possible regulatory changes, future strategic requirements, and reserve adequacy assessments based on evolving business needs.
5	Contingency / Miscellaneous	7-8	<b>6 to 9 months</b>	The contingency amount is indicative as it covers unforeseen expenses, market volatility, and cost escalations that may arise during project execution.
6	Working Capital	53-59	<b>12 to 18 months</b>	Working capital requirements may vary owing to fluctuations in operating cycles, inventory levels, credit terms, and overall business volume.
	<b>Total</b>	153.25		

## **Business Expansion Brief – Integrated Health, Wellness & Pharmaceutical Division**

### **1. Overview**

The Company is undertaking a strategic expansion into the Integrated Health, Wellness, and Pharmaceutical Sector, featuring an extensive product portfolio,

This initiative aligns with the Company's long-term strategy of building a diversified, science-driven, and sustainable healthcare enterprise, catering to consumer, clinical, and institutional segments.

The expansion strengthens the Company's presence in Nutraceuticals, Cosmeceuticals, Pet Healthcare, and Generic Pharmaceuticals — all rapidly growing markets offering strong domestic and global potential.

## 2. Business Segments

### a. Pet Care Division

The Pet Care Division focuses on functional nutrition, dermatology, and therapeutic wellness for companion animals.

#### Key Categories:

- **Functional Foods:** Advanced formulations supporting gut health, mobility, immunity, and overall wellness.
- **Nutritional Supplements:** Enriched with vitamins, minerals, amino acids, and probiotics for different breeds and life stages.
- **Cosmeceutical & Dermaceutical Line:** Products addressing allergies, skin infections, and coat enhancement, formulated with natural and clinical actives.
- **Durecal Therapeutic Range:** Disease-specific nutritional support for chronic and post-surgical recovery (hepatic, renal, and cardiac care).

#### Retail & E-Commerce Strategy:

The Company will launch a dedicated Pet Wellness Brand supported by a multi-channel model, including:

- A proprietary e-commerce platform for direct-to-consumer (D2C) sales,
- Integration with major marketplaces (Amazon, Flipkart, and niche pet platforms),
- Partnerships with veterinary clinics, grooming centers, and retail outlets, and
- Subscription-based models for regular wellness product delivery.

This ensures nationwide reach, digital scalability, and brand consistency across all customer touchpoints.

### b. Human Care Division

The Human Care Division will address lifestyle-driven health challenges through nutritional, cosmeceutical, and dermatological solutions.

#### Key Categories:

- **Nutritional Products:** Functional foods and nutraceuticals focusing on immunity, metabolism, cardiac, and bone health.
- **Cosmeceuticals:** Skincare products that combine cosmetic appeal and pharmaceutical-grade performance using bioactive peptides, antioxidants, and natural extracts.

- Dermatological Range: Medicated formulations addressing acne, eczema, and scalp health — co-developed with dermatologists for clinical efficacy and compliance

### **c. Pharma Generics Division**

The Pharma Generics Division represents the Company's entry into the regulated pharmaceutical market, focusing on cost-effective, high-quality generic formulations for both domestic and international markets.

Dosage Forms: Tablets, capsules, oral liquids, ointments, powders, and injectables — manufactured under GMP and WHO-compliant facilities.

### **3. Strategic Vision**

The Company's mission is to evolve into a comprehensive, science-led, and ethically governed enterprise, bridging Nutrition, Dermatology, and Pharmaceuticals for both humans and animals.

### **4. Proposed Fund Allocation**

<b>Use of Funds</b>	<b>Approximate Allocation (%)</b>
Brand Marketing & Distribution	35%
CAPEX (Plant, Machinery, Infrastructure)	5%
Formulation Development & R&D	5%
Working Capital	35%
Strategic & Statutory Reserves	15%
Contingency / Miscellaneous	5%
<b>Total</b>	<b>100%</b>

### **Countries targeted initial for expansion is as stated below.**

Srilanka, Philippines, Nigeria, Togo, Ivory Coast, Zambia, Iran, UAE, Mali